Vectalys set up its therapeutic unit, Flashcell and stayed focused on its manufacturing activity. Considering that safe & efficient delivery combined with manufacturing know-how is a therapeutic key of success, Vectalys has legitimately included therapeutic applications to its activities.
Vectalys sub-licensed in 2017 its new LentiFlash® technology and rights to the clinical-stage biotechnology company, FlashCell, for a wide range of therapeutic applications including immunotherapy and gene editing approaches. In 2017, FlashCell carried out research programs to complete the intellectual portfolio and identify its own clinical programs.
A result of the merger of Vectalys & FlashCell, Flash Therapeutics is a new leading integrated player with a new brand and a complete integrated offer. Flash Therapeutics will include both a manufacturing platform named Vectalys by Flash and a new therapeutic gene therapy unit.
First lentiviral vectors GMP batch from the Vectalys by Flash GMP Manufacturing Platform of Flash Therapeutics.
15M€ financing agreement with TechLife Capital and Elaia Partners over 3 years to ensure the growth of its production capacities to industrial and clinical standards (GMP).
Flash Therapeutics announced to double its clinical batch production capacity by 2022 and expand to large-scale batch manufacturing starting 2023.
Flash Therapeutics establishes its new biomanufacturing platform in Toulouse.
Flash Therapeutics obtained a grant of €1.5M from the French government for the clinical manufacture of batches of LentiFlash® particles enabling the delivery of RNA as early as 2022 to manufacture a candidate RNA vaccine against COVID-19 by the end of 2022.
Flash Therapeutics obtained a grant of €1M from the Occitanie Region to support the development of RNA/DNA technologies for gene transfer.